David Christopher Eustice, Ph.D.

7 Granite Ridge Rd.

Redding, CT 06896
(203) 605-8334
dceustice@optimum.net

OBJECTIVE: Senior Scientist / Group Leader position

Profile:
My expertise is in team building, assay development and HTS
operations with diversified experience in target selection, assay
design, validation, and automation. Particular emphasis has been
in the fields of assay design, molecular target optimization,
enzymology, HTS automation, cell-free receptor-based screens, and
drug discovery. Extensive hands-on experience with HTS
operations and detailed experience with mechanism of action
studies at the biochemical level.
I have additional experience in co-developing LIMS systems
for Bayer Pharmaceuticals and CGI pharmaceuticals, field
applications, field support, market analysis, and sales.

KEYWORDS: biochemistry, enzymology, HTS, small-molecule drug-

discovery, automation, LIMS, in vitro assays, mechanism of
action, FRET

PROFESSIONAL EXPERIENCE:

Paier College of Art

Adjunct Professor of Biology Jan 2010-

• Hired to teach 2 courses in Environmental Biology

CGI Pharmaceuticals, Branford, CT. 2009-

Independent Contract Scientist

• Invited to return to CGI Pharmaceuticals to investigate and

correct several biochemical receptor tyrosine kinase assays
which were not performing up to specifications.
• Also hired to test and ensure that several other RT kinase
cross-screen assays are performing up to specifications.

Greenwich Science Center 2007-

Executive Director
• Created the science center to disseminate science and
technology information.
• Developed extensive networks and partnerships between
industries and organizations to achieve the goals of
the science center.
Cara Therapeutics, Tarrytown, NY. 2006–2007
Associate Director of Molecular Screening.

• Helped establish in-house technologies and incorporated

external cell-based technologies for orphan GPCR screening
(DiscoverX) based on down stream signaling cascades.
• Established a set of Cyp P450 Inhibition assays for Cara’s
ADME profiling efforts.

Tomtec Instruments, Hamden, CT. 1/06-7/06

Sales Engineer and Application Specialist,

• Market assessment of the Connecticut sales opportunities

(Biotech, Pharmas, Diagnostics.) Provided global
application support for (30K-200K) capital equipment.
• Home office based position requiring direct interaction
with Tomtec engineers and software programmers. Provided
feedback from customers to meet market needs.

CGI Pharmaceuticals, Branford, CT. 2002–2006

Principal Scientist

• Established the HTS facility at CGI Pharma to support in-

house drug discovery programs for kinases.
• Created the HSAD (High Speed Assay Development) system
using FRET and SPA assay formats that is part of CGI
Pharmaceuticals HALO platform.
• The HSAD system allowed CGI Pharma to rapidly validate
over 50 kinases in 3 assay formats.
• Successfully discovered HTS hits that led to CGI
Pharmaceuticals first multiplex drug development candidate
(cgi 1842) for angiogenesis inhibition (now n phase I
clinical trials) and the BTK inhibitor program.
• Extensive experience with enzyme kinetics and mechanism of
action studies.
• Coordinator for all in vitro CRO studies.

Bayer Corp., West Haven, CT. 1994-2002

Senior Staff Scientist, High throughput DNA Sequencing.

• Over four years as the manager of the high throughput DNA

Sequencing Center for the Genomics group at Bayer.
• Participated in the target evaluation team for the
Millenium collaboration.
Senior Staff Scientist, Head of Robotics/Automation. 1994-1997

• Designed and implemented two robotic systems for HTS

operations at Bayer.
• Designed and implemented the compound library compression
scheme that allows for the screening of >100,000 per week
with automatic de-compression/decoding features.

Senior Staff Scientist, Head of HTS Unit. 1994-1995

• Established the infrastructure of the HTS operation.

• Co-designed and co-developed the database system for the
HTS Unit.
• Initiated the design and implementation of the automated
compound repository system and the MTP storage/inventory
system.

Bristol-Myers Squibb Co., Wallingford, CT. 1991-1994

Senior Research Investigator (II). Microbial Biochemistry and
Genetics Dept.

• Responsible for the diversification of Natural Products

Drug Discovery program into new therapeutic areas.
• Primary goals were to design, validate, and operate novel
targeted assays for drug discovery in most of the
pharmaceutically relevant therapeutic areas of company
interest.

E.I. Dupont de Nemours Co., Inc. 1985-1991

Principle Investigator. Viral Diseases Group 1989-1991

• Responsible for the anti-influenza program.

• Primary goals were to establish a drug discovery program
based on cell-free assay systems for viral RNA synthesis.
• The approach combined elements of high throughput
mechanism-based screens as well as a rational design
program.

Research Biochemist. Medical Products Division 1985-1989

• Hired to determine the mechanism of action of existing drug

candidates in the antibacterial program and to design
mechanism-based assays for the discovery efforts.

University of Rochester, Rochester, NY

Post Doctoral Fellow, Dept. of Biochemistry 1984-1985
Post Doctoral Fellow, Dept. of Microbiology 1981-1984

Dartmouth Medical School, Hanover, NH 1980-1981

Post Doctoral Fellow, Depts. of Pharmacology and Toxicology,

PROFESSIONAL MEMBERSHIPS: INTERESTS

Member of the Society for Biomolecular Sciences and New England
LRIG. Other interests include golfing and Tang Soo Do Mi Guk
Kwan Assoc. (Cho Dan)

EDUCATION:
Ph.D. Dept. of Biology, SUNY at Binghamton, NY.
M.A. Dept. of Biology, SUNY at Geneseo, NY.
B.S Dept. of Biology, SUNY at Geneseo, NY.

PUBLICATIONS:
Scott A. Mitchell, Mihaela Diana Danca, Peter A. Blomgren, James
W. Darrow, Kevin S. Currie, Jeffrey E. Kropf, Seung H. Lee,
Steve Gallion, Jin-Ming Xiong, Douglas Pippin, Robert DeSimone,
David R. Brittelli, David Eustice, Aaron Bourret, Melissa Hill,
Pat Maciejewski, and Lisa Elkin. In Press. 2010.
Imidazo[1,2-a]pyrazine diaryl ureas: Inhibitors of the
receptor tyrosine kinase EphB4. In Press: Bioorganic and
Medicinal Chemistry Letters
Lathrop, W., J. Jordan, D. Eustice, and David Chen. 1999. Rat
osteotesticular phosphatase gene (Esp): genomic structure and
chromosome location. Mammalian Genome, 10,366-370.
Golik,J., Joyce K. Dickey, Gordon Todderud, Deborah Lee, Julie
Alford, Sella Huang, Steven Klohr, David Eustice, Alejandro
Aruffo, and Michele L. Agler. 1997. Isolation and Structure
Determination of
Sulfonoquinovosyl Dipalmitoyl Glyceride, a P-selectin Receptor
Inhibitor from the Alga Dictyochloris fragrans. Journal of
Natural Products, 60(4): 387-389.
Jamil, H., D.A. Gordon, D.C.Eustice, C.M. Brooks, J.K. Dickson,
Jr., Y. Chen, B. Ricci, C-H. Chu, T.W. Harrity, C.P. Ciosed,
Scott A. Biller, ZR.E. Gregg, and J.R. Wetterau. 1996.
An Inhibitor of the microsomal triglyceride transfer protein
inhibits ApoB secretion from HepG2 cells. PNAS 93(21): 11991-
11995.
J.Bajortath, D. Hollenbaugh, G. King, W. Harte, Jr., D.C.
Eustice, R.P. Darveau and A. Aruffo. 1994. The CD62/P-Selectin
Sites for Myeloid Cells and Sulfatides are Overlapping.
Biochemistry, 33(6): 1332-1339.
Eustice, D.C., P.A. Feldman, A. Colberg-Poley, R.M. Buckery, and
R.H. Neubauer. 1991. An automatable method for the detection
of beta-galactosidase. Biotechniques, 11(6): 739-742.
Otto, M.J. and D.C. Eustice. 1991. New Approaches to Antiviral
 Therapy. Drug News and Perspectives.
Eustice, D.C., Brittelli, D.R., P.A. Feldman, Brown, L.J.,
Borkowski, J.J. ,and A.M. Slee. 1990. An automated pulse
labeling method for structure-activity relationship studies
with the antibacterial oxazolidinones. Drugs Under Exp. and
Clin. Res., XVI(4): 149-155.
Dumont, M.E., B.T. Nall, S.B. Baim, D.C. Eustice, and F. Sherman.
1990. Differential stability of two apo-iso-cytochrome c in
the Yeast Saccharomyces cerevisie. J. Biol. Chem., 265(5):
2733-2739.
W.A. Gregory, D.R. Brittelli, C-L.J. Wang, M.A. Wuonola, R.J.
McRipley, D.C. Eustice, V.S. Eberly, A.M. Slee, and M. Forbes.
1989. Antibacterials. Synthesis and Structure-Activity Studies
of 3-aryl-2-Oxoxazolidinones 1. The "B-group". J. Med. Chem.,
32: 1673-1681.
Eustice, D.C., P.A. Feldman, I. Zajac, and A.M. Slee. 1988. The
Mechanism of action of DuP 721: Inhibition of an Early Event
During the Initiation of Protein Synthesis. Antimicro. Agents
and Chemother. 32(8): 1218-1222.
Eustice, D.C., P.A. Feldman, and A.M. Slee. 1988. The mechanism
of action of DuP 721, a new antibacterial agent: effects on
macromolecular synthesis. Biochem. Biophys. Res. Com.,
150(3):965-971.
Eustice, D.C., L.P. Wakem, J.M. Wilhelm, and F. Sherman. 1986.
Altered 40 S ribosomal subunits in omnipotent suppressors of
yeast. J. Mol. Biol., 188:207-214.
Zurlo,J., D.C. Eustice, J.E. Mignano, M.C. Poirier, and J.D.
Yager. 1986. Effects of carcinogen treatment on rat liver DNA
Synthesis in vivo and on nascent DNA synthesis and elongation
in cultured hepatocytes. Mut. Res., 161:143-154.
Baim, S., C.T. Goodhue, D.F. Pietras, D.C. Eustice, M. Labhard,
L.R. Friedman, D.M. Hampsey, J.I. Stiles, and F. Sherman.
1985. Rules of translation: studies with altered forms of the
yeast CYC1 gene. In: Sequence specificity in transcription
and translation. Alan R. Liss, Inc.
Baim, S., D.F. Pietras, D.C. Eustice, and F. Sherman, 1985. A
mutation allowing a mRNA secondary structure diminishes
translation of yeast iso-l-cytochrome c. Mol. Cell. Biol.,
5(8):1839-1846.
Eustice, D.C. and J.M. Wilhelm. 1984. Mechanisms of action of
aminoglycoside antibiotics in eukaryotic protein synthesis.
Antimicrob. Agents and Chemotherapy, 26:53-60.
Eustice, D.C. and J.M. Wilhelm. 1984. Fidelity of the
Eukaryotic codon-anticodon interaction: interference by
Aminoglycoside antibiotics. Biochemistry, 23:1462-1467.
Eustice, D.C., F.J. Kull, and A. Schrift. 1981. In vitro
incorporation of selenomethionine into protein by Astragalus
polysomes., Plant Physiol.,67:1059-1060.
Eustice, D.C., F.J. Kull, and A. Schrift. 1981. Selenium
Toxicity: aminoacylation and peptide bond formation with
selenomethionine., Plant Physiol.,67:1054-1058.
Eustice, D.C., I. Foster, F.J. Kull, and A. Schrift. 1981. In
 Vitro incorporation of selenomethionine into protein by Vigna
radiata polysomes., Plant Physiol.,66:183-186.
Eustice, D.C. 1980. In vitro utilization of selenomethionine
during protein synthesis in selenium-tolerant and selenium
sensitive plants. Ph.D. Dissertation, SUNY at Binghamton, NY.
Abstracted in Dissertation Abstracts International: 41:138-B.
Byng, G.S., D.C. Eustice, and R.A. Jensen. 1979. Biosysthesis
of phenazine pigments in mutant and wild type cultures of
Pseudomonas aeruginosa. J. Bact., 138:846-852.
Latorella, A.H., D.C. Eustice, P. Regan, and C. Mischke. 1978.
The regulation of DNA replication during senescence and
rejuvenation in Dunaliella tertiolecta by factors other than
available metabolic energy., Exp. Cell Res. 117: 293-299.

ABSTRACTS PUBLISHED:

Too numerous to list but, a few recent ones that are relevant are
listed below.

David Eustice, Melissa Hill, Pat Maciejewski, Robert Desimone and

Dapeng Qian. 2004. High Speed Assay Development for Kinases.
Poster #P0029, SBS 10th Anniversary Conference and Exhibition.
D. Qian, S. Srinivasa, S. Mitchell, L Elkin, D. Eustice,
J.Barbosa, Barbosa, A.Whitney, D. Pippin, J. Darrow, J. Di
Paulo, S. Chaudhuri, M. Hill, P. Maciejewski, R. DeSimone, X.
Qian, M. Velleca. 2004 Discovery and development of multiplex
angiogenesis inhibitors that target EphB4: Validation with a
novel chemical-genetics based in vivo model. AACR Molecular
Targets Cancer Therapy
Dapeng Qian, Kevin Currie, Julie Di Paolo, Jim Barbosa, Dave
Eustice, Jim Darrow, Jeff Kropf, Doug Pippin, Krista Geist,
Jane Mayotte, Pat Maciejewski, Melissa Hill, Dianna Elwood,
Guoju Geng, Jin Duan, Jin Ming Xiong, Linda Malicki, Paula
King, Peter Fowles, Philip Rosner, Shan Jiang, Subhra
Chaudhuri, Tony Lee, Scott Mitchell, Lisa Elkin, Steve
Gallion, Andy Whitney, Tom Stephan, Dave Brittelli, Xiaobing
Qian, Ud Klein, Mark Velleca. 2004. Discovery and
Optimization of Potent and Highly Selective Inhibitors of
Bruton's Tyrosine Kinase (BTK) for the Treatment of
Autoimmune/inflammatory Disease. 12th International
Congress on Immunology, Montreal
Kevin S. Currie, Rob DeSimone, Lisa Elkin, David Eustice, Susanne
Heck, Scott Mitchell, Doug Pippin, Dapeng Qian and Xiaobing
Qian. 2003 Discovery and Optimization of Potent, Selective
Small Molecule Inhibitors of Bruton's Tyrosine Kinase. IBC
Drug Discovery for Inflammatory Diseases, Vienna, VA.